PET imaging of chemokine receptor CXCR4 in patients with primary and recurrent breast carcinoma

EJNMMI Research

Table 3 Immunohistochemical assessment for CXCR4 in surgical specimens

Patient #	Subtype	Immune cells	Immune cell positivity (%)	Tumor cells	Tumor cell positivity (%)	Overall signal strength	SUVmax
3	ILC	+	0	−	0	−	1.7
5	NST	+++	40	++	15	++	2.9
6	NST	++	5	++	5	+	1.9
7	NST	++	10	+++	2	+	2.8
8	NST	+	5	+	0	−	3.2
10	ILC	−	0	+	20	+	1.8
11	NST	+++	20	+	20	++	1.8

Degree of immune cell infiltration was scored from (−) (no infiltration) to (+++) (strong infiltration). Staining intensity for tumor cells was scored from (−) (no expression) to (+++) (strong expression). Percentage amount of CXCR4-positive immune and tumor cells in the specimens (positivity) is shown in the third and fifth columns. The last columns show overall signal intensity and corresponding SUVmax during PET CXCR4-directed PET imaging respectively

Patient #	Subtype	Immune cells	Immune cell positivity (%)	Tumor cells	Tumor cell positivity (%)	Overall signal strength	SUVmax
3	ILC	+	0	−	0	−	1.7
5	NST	+++	40	++	15	++	2.9
6	NST	++	5	++	5	+	1.9
7	NST	++	10	+++	2	+	2.8
8	NST	+	5	+	0	−	3.2
10	ILC	−	0	+	20	+	1.8
11	NST	+++	20	+	20	++	1.8

Patient #	Subtype	Immune cells	Immune cell positivity (%)	Tumor cells	Tumor cell positivity (%)	Overall signal strength	SUVmax
3	ILC	+	0	−	0	−	1.7
5	NST	+++	40	++	15	++	2.9
6	NST	++	5	++	5	+	1.9
7	NST	++	10	+++	2	+	2.8
8	NST	+	5	+	0	−	3.2
10	ILC	−	0	+	20	+	1.8
11	NST	+++	20	+	20	++	1.8

Patient #	Subtype	Immune cells	Immune cell positivity (%)	Tumor cells	Tumor cell positivity (%)	Overall signal strength	SUVmax
3	ILC	+	0	−	0	−	1.7
5	NST	+++	40	++	15	++	2.9
6	NST	++	5	++	5	+	1.9
7	NST	++	10	+++	2	+	2.8
8	NST	+	5	+	0	−	3.2
10	ILC	−	0	+	20	+	1.8
11	NST	+++	20	+	20	++	1.8